What is 5-Amino-1MQ and how does it work?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small, membrane-permeable molecule that selectively inhibits the enzyme nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide using SAM as the methyl donor; when it is overactive - as in obese or aged tissue - it acts as a methyl sink that drains both the NAD+ and SAM pools. By blocking NNMT selectively, 5-Amino-1MQ spares nicotinamide for NAD+ biosynthesis and preserves SAM for other methylation reactions. It is supplied for laboratory research only, not for human use.

What does the 5-Amino-1MQ research actually show?

The evidence is entirely preclinical. In high-fat-diet mouse models, 5-Amino-1MQ has been reported to reduce body weight, white adipose mass and adipocyte size and to improve grip strength (Neelakantan et al., PNAS, 2022), and a 2024 study reported that NNMT inhibition improved glucose tolerance and fatty-liver markers without reducing food intake (Babula et al., Diabetes Obesity and Metabolism; PMID 39161060). There is no published human clinical efficacy. It is not approved for any indication in any jurisdiction.

How is 5-Amino-1MQ different from MOTS-C?

Both are studied for metabolism, but they are structurally and mechanistically different. 5-Amino-1MQ is a small-molecule NNMT inhibitor that preserves NAD+/SAM pools and is taken orally; MOTS-C is a 16-amino-acid mitochondrial-derived peptide that activates AMPK as an exercise mimetic and is injected. One is an oral enzyme inhibitor, the other an injectable signalling peptide.

How is 5-Amino-1MQ stored, and is it legal?

Unlike most peptides, 5-Amino-1MQ is a stable small molecule that does not need freezing - store it in a cool, dry place at room temperature. It is not approved for human therapeutic use and is supplied strictly as unapproved research-grade material for laboratory use, not for human consumption. Legal status varies by jurisdiction, so confirm your local rules before purchasing.

How-to guides

5-Amino-1MQ: The NNMT-Inhibitor Research Guide (Fat Loss & NAD+ Longevity)

Q: Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small molecule (5-amino-1-methylquinolinium), not a peptide. It sits in the metabolic research toolkit because it targets an enzyme pathway - NNMT - that governs the same NAD+ and SAM pools that peptide-based metabolic research often tries to influence. It is also handled differently from peptides: it is orally bioavailable and shelf-stable at room temperature rather than a lyophilised, cold-stored injectable.

Quick answer: 5-Amino-1MQ is the outlier on a peptide site - it is a small molecule, not a peptide . It selectively blocks the enzyme NNMT (nicotinamide N-methyltransferase), which in obese and aged tissue acts as a "methyl sink" draining the cell's NAD+ and SAM pools. In diet-induced-obesity mouse models it has been reported to shrink fat cells, lower body weight and even improve grip strength. It is orally bioavailable, shelf-stable, and studied entirely in preclinical work - supplied for research use only, not for human use .

Why a small molecule is on a peptide site. 5-Amino-1MQ belongs to the metabolic research toolkit for the same reason NAD+ precursors and AMPK activators do - it targets the NAD+/SAM biology that peptide metabolic research also chases. We describe the mechanism and the evidence; nothing here is a dose, a protocol, or medical advice.

What 5-Amino-1MQ actually is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small, membrane-permeable molecule that inhibits nicotinamide N-methyltransferase (NNMT) . That enzyme takes nicotinamide and methylates it into 1-methylnicotinamide, using SAM (S-adenosylmethionine, the cell's universal methyl donor) in the process. At baseline that reaction is fine - but in obese adipose tissue and aged cells NNMT is often dramatically upregulated, and it becomes a "methyl sink" : every nicotinamide it burns is one that can no longer be recycled into NAD+ , and every SAM it consumes is one unavailable for the rest of the cell's methylation reactions.

The mechanism, step by step

Selectively shutting off NNMT does two things at once, and both are the point:

NAD+ preservation. Sparing nicotinamide keeps it available for NAD+ biosynthesis, which feeds SIRT1 signalling and downstream metabolic regulation.

SAM preservation. Keeping the universal methyl donor intact supports the epigenetic methylation reactions that depend on it.

Lipogenesis suppression. In adipocytes, restored NAD+/SIRT1 tone is associated with reduced de-novo fat synthesis - the mechanistic route to the leaner adipose profile seen in the animal data.

Critically, the compound is selective : Neelakantan et al. (Biochemical Pharmacology, 2018) developed it specifically to spare closely related SAM-dependent methyltransferases, so it targets the NNMT methyl-sink without broadly disrupting methylation.

What the research shows - and where it stops

The honest summary: the evidence is entirely preclinical . There is no published human efficacy data.

Neelakantan et al. (PNAS, 2022) - in high-fat-diet mice, 5-Amino-1MQ was reported to reduce body weight, white adipose mass and adipocyte size, and to improve grip strength beyond exercise alone (an unusual finding for a fat-metabolism compound).

Babula et al. (Diabetes, Obesity and Metabolism, 2024; PMID 39161060) - NNMT inhibition limited body-weight and fat-mass gain and improved glucose tolerance and fatty-liver markers in diet-induced obese mice, notably without reducing food intake - pointing to an adipose/energy-expenditure mechanism rather than appetite suppression.

Rat pharmacokinetics are unusually favourable for a metabolic small molecule: roughly 38% oral bioavailability , a plasma half-life around 3.8 h (IV) / 6.9 h (oral), very high water solubility, and no genotoxicity signal across Ames, micronucleus and in-vivo assays. No human PK has been published.

Preclinical means preclinical. Every result above comes from rodent models and rat pharmacokinetics. 5-Amino-1MQ is not approved for any indication in any jurisdiction and is supplied as unapproved laboratory material for research use only - not for human use . Nothing here is a dose recommendation or medical advice.

5-Amino-1MQ vs the peptides: how it's different

Two practical differences set it apart from most of the New-U catalog:

Structure & route. It is an oral small molecule, not an injectable peptide - which is exactly why the ~38% oral bioavailability matters.

Handling. Unlike lyophilised peptides that need freezing and reconstitution, 5-Amino-1MQ is a crystalline solid that is shelf-stable at room temperature (see the storage guide for how it contrasts with peptide handling).

The closest conceptual neighbour on the site is MOTS-C - but that is a 16-amino-acid mitochondrial-derived peptide that activates AMPK as an "exercise mimetic" and is injected. One is an oral enzyme inhibitor; the other an injectable signalling peptide. For the wider longevity-research map it sits within, see peptides & healthy-aging research (2026) and its metabolic siblings SS-31 and Epitalon.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide? No - it is a small molecule (5-amino-1-methylquinolinium). It is grouped with metabolic research compounds because it acts on the NNMT/NAD+/SAM pathway that peptide metabolic research also targets, but structurally and in handling it is quite different: oral and room-temperature stable.

How does NNMT inhibition relate to NAD+? NNMT methylates nicotinamide into 1-methylnicotinamide. Every nicotinamide it consumes is one that can no longer be recycled into NAD+. When NNMT is overactive (as in obese adipose tissue) it drains that pool; blocking it with 5-Amino-1MQ preserves nicotinamide for NAD+ regeneration.

What does the data actually show? Preclinical only: reduced body weight, adipose mass and adipocyte size plus improved grip strength in mice, and improved glucose tolerance without appetite suppression in a 2024 obesity study. No human efficacy has been established.

How should it be stored? As a stable small molecule it does not require freezing - keep it in a cool, dry place at room temperature. That is a key handling contrast with the lyophilised, cold-stored peptides elsewhere on the site.

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

5-Amino-1MQ: The NNMT-Inhibitor Research Guide (Fat Loss & NAD+ Longevity)

What 5-Amino-1MQ actually is

The mechanism, step by step

What the research shows - and where it stops

5-Amino-1MQ vs the peptides: how it's different

Frequently Asked Questions

Related Reading

From the Lab - Peptides on LinkedIn & Facebook

5-Amino-1MQ, Lab-Verified.

Buy research peptides from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide